Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms KINECT-3
  • Sponsors Neurocrine Biosciences

    • Most Recent Events

    • 02 Jun 2023 According to a Neurocrine Biosciences Media Release, data were presented at 2023 Psych Congress Elevate in Las Vegas.
    • 02 Jun 2023 Results of 3 studies (KINECT 3, KINECT 4 & J-KINECT) presented in a Neurocrine Biosciences Media Release.
    • 15 May 2023 According to an Neurocrine Biosciences media release, findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™ 4) were presented at the Schizophrenia International Research Society (SIRS) 2023 Annual Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top